Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

[1] Al-Daraji WI(2009)Infection and cervical neoplasia: facts and fiction Int J Clin Exp Pathol 2 48-64

[2] Smith JH(2005)Global cancer statistics, 2002 CA Cancer J Clin 55 74-108

[3] Parkin DM(2006)Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases Vaccine 24 S26-S34

[4] Bray F(2003)Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518-527

[5] Ferlay J(2004)Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int J Cancer 111 278-285

[6] Pisani P(2008)Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia Vaccine 26 K1-K16

[7] Clifford G(2009)A review of human carcinogens–Part B: biological agents Lancet Oncol 10 321-322

[8] Franceschi S(2007)Parental intention to have daughters receive the human papillomavirus vaccine Can Med Assoc J 177 1506-1512

[9] Diaz M(2006)Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine 24 5937-5949

[10] Muñoz N(2009)Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 301-314

[1] Al-Daraji WI(2009)Infection and cervical neoplasia: facts and fiction Int J Clin Exp Pathol 2 48-64

[2] Smith JH(2005)Global cancer statistics, 2002 CA Cancer J Clin 55 74-108

[3] Parkin DM(2006)Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases Vaccine 24 S26-S34

[4] Bray F(2003)Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518-527

[5] Ferlay J(2004)Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int J Cancer 111 278-285

[6] Pisani P(2008)Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia Vaccine 26 K1-K16

[7] Clifford G(2009)A review of human carcinogens–Part B: biological agents Lancet Oncol 10 321-322

[8] Franceschi S(2007)Parental intention to have daughters receive the human papillomavirus vaccine Can Med Assoc J 177 1506-1512

[9] Diaz M(2006)Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine 24 5937-5949

[10] Muñoz N(2009)Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 301-314